AMULET superior to WATCHMAN in peridevice leak at 12 months: clinical impact unknown
Key Points The AMULET Left Atrial Appendage Occluder was shown to be noninferior to the Watchman device for patients with atrial fibrillation; results of the AMULET-IDE... Read more.
SURTAVI: self-expanding TAVR continues to perform against SAVR 5 years out
Key Points The SURTAVI trial randomized patients at intermediate risk for aortic valve replacement to receive either TAVR with and without PCI using a supra-annular... Read more.
STOP-DAPT 2 Total Cohort Study: needle moving closer to one month DAPT strategy
Despite advances in therapy, the choice and duration of antiplatelet therapy following percutaneous coronary intervention (PCI) remains an area of active debate.... Read more.
Left atrial appendage closure is noninferior to NOACs for atrial fibrillation: PRAGUE-17
Key Points: In the PRAGUE-17 study, patients with non-valvular atrial fibrillation were treated with either oral anticoagulants or left atrial appendage closure... Read more.
Plug-based vascular closure device associated with more complications: CHOICE-CLOSURE
In patients with severe aortic stenosis (AS) undergoing transfemoral transcatheter aortic valve implantation (TAVI), periprocedural vascular complications are common... Read more.
Abbreviated DAPT can be safe for patients with high bleeding and ischemic risk: MASTER-DAPT substudy
Key Points: In this pre-specified MASTER DAPT sub-study, patients with high bleeding risk and high ischemic risk (the latter of which was defined as those who have... Read more.
Sweet news for new stent: SUGAR trial finds polymer-free stent non-inferior to ZES in patients with diabetes.
Key Points: Patients with diabetes who undergo PCI are more likely to have target lesion failure and target vessel revascularization than their non-diabetic counterparts.... Read more.
PCI guided by Quantitative Flow Reserve Superior to Standard Angiography: FAVOR III China
Key Points: Quantitative Flow Reserve (QFR) is a non-pressure wire method of assessing flow through the coronary arteries, using 3D reconstructions and computations... Read more.
FAME 3: PCI does not meet noninferiority to CABG in patients with three-vessel disease.
Key Points: All-comers with three vessel disease were randomized to undergo FFR-guided PCI or Coronary Artery Bypass Grafting in this multicenter, international... Read more.
STOP-DAPT 2 ACS: 1 month DAPT followed by clopidogrel monotherapy does not quite cut it when it comes to ACS
Key Points: The original STOP-DAPT trial randomized patients to receive either 12 months of dual antiplatelet therapy after percutaneous coronary intervention or... Read more.